Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Completed

• Conditions: Glaucoma, Open-Angle; Ocular Hypertension

• Registration Number: NCT00334750
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-06-05
• Study First Submitted QC: 2006-06-05
• Study First Posted: 2006-06-08
• Study Start: 2007-11
• Primary Completion: 2009-04
• Study Completion: 2009-04
• Status Verified: 2010-09
• Last Update Submitted: 2021-02-01
• Last Update Posted: 2021-02-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 410

Inclusion Criteria

• Subjects diagnosed at study visit or within 3 months of visit with OH
• OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria

• No prior treatment for OH or OAG
• No prior ocular surgery or history of ocular trauma

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.	duration of study

Secondary Outcome Measures

Name	Time	Method
To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.	duration of study

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇨🇦 Saskatoon, Saskatchewan, Canada